← Leaderboards
Yong J Lee
Cedars-Sinai Medical Center
$5,697,287
Attributed
$6,783,299
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $634.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,783,299 · 10
By mechanism
R01$5,756,491 · 5
R03$614,577 · 4
R21$412,231 · 1
Top collaborators
- David L Bartlett5 shared
- Herbert J Zeh5 shared
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeLigandsMalignant NeoplasmsBiochemicalApoptosisCombined Modality TherapyMolecularPreclinical EfficacyApplications GrantsNovel StrategiesMultimodalityOutcome StudyResearch Project GrantsMitochondriaUnited StatesCytotoxicityTnfsf10 GeneTumorProteinsResponseNeoplasm MetastasisDrug KineticsNormal CellHalf-Life
Grant awards (29)
Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastases$470,202
R01 · FY2025 · CA · contact PI
Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastases$413,158
R01 · FY2024 · CA · contact PI
Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastases$443,574
R01 · FY2023 · CA · contact PI
Application of in vivo humanized PDX mouse model and ex vivo organoid model to assess the therapeutic efficacy of combinatorial therapy for pseudomyxoma peritonei$191,278
R21 · FY2023 · CA · contact PI
Application of in vivo humanized PDX mouse model and ex vivo organoid model to assess the therapeutic efficacy of combinatorial therapy for pseudomyxoma peritonei$220,953
R21 · FY2022 · CA · contact PI
Application of a humanized patient-derived xenograft mouse model to assess the preclinical efficacy of combined chemohyperthermia and chimeric TRAIL treatment in ovarian peritoneal carcinomatosis$78,250
R03 · FY2021 · CA · contact PI
Application of a humanized patient-derived xenograft mouse model to assess the preclinical efficacy of combined chemohyperthermia and chimeric TRAIL treatment in ovarian peritoneal carcinomatosis$78,250
R03 · FY2020 · CA · contact PI
Targeted hyperthermia in combination with chimeric TRAIL and chemotherapeutic agent treatment for colorectal liver metastasis$78,250
R03 · FY2018 · CA · contact PI
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells$77,959
R03 · FY2018 · CA · contact PI
Targeted hyperthermia in combination with chimeric TRAIL and chemotherapeutic agent treatment for colorectal liver metastasis$78,209
R03 · FY2017 · CA · contact PI
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells$77,312
R03 · FY2017 · CA · contact PI
Multimodality approach to hepatic colorectal metastases$342,780
R01 · FY2014 · CA · contact PI
Multimodality approach to hepatic colorectal metastases$336,991
R01 · FY2013 · CA · contact PI
Multimodality approach to hepatic colorectal metastases$346,211
R01 · FY2012 · CA · contact PI
Multimodality approach to hepatic colorectal metastases$357,804
R01 · FY2011 · CA · contact PI
Multimodality approach to hepatic colorectal metastases$245,232
R01 · FY2010 · CA · contact PI
Metabolic Oxidative Stress and TRAIL Cytotoxicity$250,632
R01 · FY2007 · CA · contact PI
Role of Glutaredoxin in Metabolic Oxidative Stress$230,921
R01 · FY2007 · CA · contact PI
Nutrients and Prostate Cancer Prevention$72,097
R03 · FY2007 · CA · contact PI
Metabolic Oxidative Stress and TRAIL Cytotoxicity$258,118
R01 · FY2006 · CA · contact PI
Role of Glutaredoxin in Metabolic Oxidative Stress$237,817
R01 · FY2006 · CA · contact PI
Nutrients and Prostate Cancer Prevention$74,250
R03 · FY2006 · CA · contact PI
Metabolic Oxidative Stress and TRAIL Cytotoxicity$264,330
R01 · FY2005 · CA
Role of Glutaredoxin in Metabolic Oxidative Stress$243,540
R01 · FY2005 · CA
Metabolic Oxidative Stress and TRAIL Cytotoxicity$264,330
R01 · FY2004 · CA
Role of Glutaredoxin in Metabolic Oxidative Stress$243,881
R01 · FY2004 · CA
Metabolic Oxidative Stress and TRAIL Cytotoxicity$265,220
R01 · FY2003 · CA
STRESS RESPONSES IN MAMMALIAN CELLS$271,100
R01 · FY2001 · CA
STRESS RESPONSES IN MAMMALIAN CELLS$270,650
R01 · FY2000 · CA